Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 2986460, 11 pages
https://doi.org/10.1155/2017/2986460
Review Article

Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer’s Disease

1Department of Anesthesiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China
2Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
3Department of Nephrology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
4Department of Clinical Trial Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China

Correspondence should be addressed to Ting Lin; moc.361@131gnitnil and Bingtian Bi; nc.gro.ccusys@tbib

Received 1 January 2017; Revised 15 February 2017; Accepted 22 March 2017; Published 3 April 2017

Academic Editor: Paula I. Moreira

Copyright © 2017 Jingdun Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. D. Sloane, S. Zimmerman, C. Suchindran et al., “The public health impact of Alzheimer's disease, 2000–2050: potential implication of treatment advances,” Annual Review of Public Health, vol. 23, pp. 213–231, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. H. W. Querfurth and F. M. LaFerla, “Alzheimer's disease,” New England Journal of Medicine, vol. 362, no. 4, pp. 329–344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Rubio-Perez and J. M. Morillas-Ruiz, “A review: inflammatory process in Alzheimer's disease, role of cytokines,” The Scientific World Journal, vol. 2012, Article ID 756357, 15 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Lemere and E. Masliah, “Can Alzheimer disease be prevented by amyloid-Β immunotherapy?” Nature Reviews Neurology, vol. 6, no. 2, pp. 108–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Nicoll, D. Boche, and C. Holmes, “Amyloid-β vaccination for Alzheimer's dementia,” The Lancet, vol. 372, no. 9647, pp. 1381–1382, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Vellas, “Tarenflurbil for Alzheimer's disease: a ‘shot on goal’ that missed,” The Lancet Neurology, vol. 9, no. 3, pp. 235–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Salloway, R. Sperling, N. C. Fox et al., “Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer's disease,” New England Journal of Medicine, vol. 370, no. 4, pp. 322–333, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. R. S. Doody, R. G. Thomas, M. Farlow et al., “Phase 3 trials of solanezumab for mild-to-moderate alzheimer's disease,” New England Journal of Medicine, vol. 370, no. 4, pp. 311–321, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Cunningham, “Microglia and neurodegeneration: the role of systemic inflammation,” GLIA, vol. 61, no. 1, pp. 71–90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. L.-G. Bodea, Y. Wang, B. Linnartz-Gerlach et al., “Neurodegeneration by activation of the microglial complement-phagosome pathway,” Journal of Neuroscience, vol. 34, no. 25, pp. 8546–8556, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. S. D. Mhatre, C. A. Tsai, A. J. Rubin, M. L. James, and K. I. Andreasson, “Microglial malfunction: the third rail in the development of Alzheimer's disease,” Trends in Neurosciences, vol. 38, no. 10, pp. 621–636, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. J. H. Wang, X. R. Cheng, X. R. Zhang et al., “Neuroendocrine immunomodulation network dysfunction in SAMP8 mice and PrP-hAbetaPPswe/PS1DeltaE9 mice: potential mechanism underlying cognitive impairment,” Oncotarget, vol. 7, no. 17, pp. 22988–23005, 2016. View at Google Scholar
  13. J. C. Lambert, S. Heath, G. Even et al., “Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease,” Nature Genetics, vol. 41, no. 10, pp. 1094–1099, 2009. View at Publisher · View at Google Scholar
  14. P. Hollingworth, D. Harold, R. Sims et al., “Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease,” Nature Genetics, vol. 43, no. 5, pp. 429–435, 2011. View at Google Scholar
  15. A. C. Naj, G. Jun, G. W. Beecham et al., “Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease,” Nature Genetics, vol. 43, no. 5, pp. 436–441, 2011. View at Google Scholar
  16. T. Jonsson, H. Stefansson, S. Steinberg et al., “Variant of TREM2 associated with the risk of Alzheimer's disease,” The New England Journal of Medicine, vol. 368, no. 2, pp. 107–116, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. X. Cheng, J. Wu, M. Geng, and J. Xiong, “The role of synaptic activity in the regulation of amyloid beta levels in Alzheimer's disease,” Neurobiology of Aging, vol. 35, no. 6, pp. 1217–1232, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Nimmerjahn, F. Kirchhoff, and F. Helmchen, “Neuroscience: resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo,” Science, vol. 308, no. 5726, pp. 1314–1318, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. D. M. Norden and J. P. Godbout, “Review: Microglia of the aged brain: primed to be activated and resistant to regulation,” Neuropathology and Applied Neurobiology, vol. 39, no. 1, pp. 19–34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Sierra, A. C. Gottfried-Blackmore, B. S. Mcewen, and K. Bulloch, “Microglia derived from aging mice exhibit an altered inflammatory profile,” Glia, vol. 55, no. 4, pp. 412–424, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. I. R. Holtman, D. D. Raj, J. A. Miller et al., “Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis,” Acta Neuropathologica Communications, vol. 3, no. 1, p. 31, 2015. View at Publisher · View at Google Scholar
  22. R. M. Barrientos, E. A. Higgins, J. C. Biedenkapp et al., “Peripheral infection and aging interact to impair hippocampal memory consolidation,” Neurobiology of Aging, vol. 27, no. 5, pp. 723–732, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. H. D. VanGuilder, G. V. Bixler, R. M. Brucklacher et al., “Concurrent hippocampal induction of MHC II pathway components and glial activation with advanced aging is not correlated with cognitive impairment,” Journal of Neuroinflammation, vol. 8, article 138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. F. L. Heppner, R. M. Ransohoff, and B. Becher, “Immune attack: the role of inflammation in Alzheimer disease,” Nature Reviews Neuroscience, vol. 16, no. 6, pp. 358–372, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Hong, V. F. Beja-Glasser, B. M. Nfonoyim et al., “Complement and microglia mediate early synapse loss in Alzheimer mouse models,” Science, vol. 352, no. 6286, pp. 712–716, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. D. P. Schafer, E. K. Lehrman, and B. Stevens, “The ‘quad-partite’ synapse: microglia-synapse interactions in the developing and mature CNS,” Glia, vol. 61, no. 1, pp. 24–36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Kettenmann, U.-K. Hanisch, M. Noda, and A. Verkhratsky, “Physiology of microglia,” Physiological Reviews, vol. 91, no. 2, pp. 461–553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Ueno and T. Yamashita, “Bidirectional tuning of microglia in the developing brain: from neurogenesis to neural circuit formation,” Current Opinion in Neurobiology, vol. 27, pp. 8–15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. C. N. Parkhurst, G. Yang, I. Ninan et al., “Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor,” Cell, vol. 155, no. 7, pp. 1596–1609, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Miyamoto, H. Wake, A. W. Ishikawa et al., “Microglia contact induces synapse formation in developing somatosensory cortex,” Nature Communications, vol. 7, article 12540, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Jimenez, D. Baglietto-Vargas, C. Caballero et al., “Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic,” The Journal of Neuroscience, vol. 28, no. 45, pp. 11650–11661, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. C. A. Colton, R. T. Mott, H. Sharpe, Q. Xu, W. E. Van Nostrand, and M. P. Vitek, “Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD,” Journal of Neuroinflammation, vol. 3, article no. 27, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. R. De Simone, M. A. Ajmone-Cat, M. Pandolfi et al., “The mitochondrial uncoupling protein-2 is a master regulator of both M1 and M2 microglial responses,” Journal of Neurochemistry, vol. 135, no. 1, pp. 147–156, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Halle, V. Hornung, G. C. Petzold et al., “The NALP3 inflammasome is involved in the innate immune response to amyloid-β,” Nature Immunology, vol. 9, no. 8, pp. 857–865, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. T. Heneka, M. P. Kummer, A. Stutz et al., “NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice,” Nature, vol. 493, no. 7434, pp. 674–678, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. M.-H. Cho, K. Cho, H.-J. Kang et al., “Autophagy in microglia degrades extracellular β-amyloid fibrils and regulates the NLRP3 inflammasome,” Autophagy, vol. 10, no. 10, pp. 1761–1775, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Lehnardt, L. Massillon, P. Follett et al., “Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8514–8519, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Fellner, R. Irschick, K. Schanda et al., “Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia,” GLIA, vol. 61, no. 3, pp. 349–360, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Song, J. Jin, J.-E. Lim et al., “TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease,” Journal of Neuroinflammation, vol. 8, article 92, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. M. Buchanan, M. Hutchinson, L. R. Watkins, and H. Yin, “Toll-like receptor 4 in CNS pathologies,” Journal of Neurochemistry, vol. 114, no. 1, pp. 13–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Hyakkoku, J. Hamanaka, K. Tsuruma et al., “Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia,” Neuroscience, vol. 171, no. 1, pp. 258–267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Suzuki, K. Hattori, J. Hamanaka et al., “Pharmacological inhibition of TLR4-NOX4 signal protects against neuronal death in transient focal ischemia,” Scientific Reports, vol. 2, article 896, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Burguillos, M. Svensson, T. Schulte et al., “Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation,” Cell Reports, vol. 10, no. 9, pp. 1626–1638, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Balducci, A. Frasca, M. Zotti et al., “Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β-amyloid oligomers in an acute mouse model of Alzheimer's disease,” Brain, Behavior, and Immunity, vol. 60, pp. 188–197, 2017. View at Publisher · View at Google Scholar
  45. E. D. Ponomarev, T. Veremeyko, N. Barteneva, A. M. Krichevsky, and H. L. Weiner, “MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway,” Nature Medicine, vol. 17, no. 1, pp. 64–70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Y. Li, J. G. Cui, P. Dua, A. I. Pogue, S. Bhattacharjee, and W. J. Lukiw, “Differential expression of miRNA-146a-regulated inflammatory genes in human primary neural, astroglial and microglial cells,” Neuroscience Letters, vol. 499, no. 2, pp. 109–113, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Y. Li, J. G. Cui, J. M. Hill, S. Bhattacharjee, Y. Zhao, and W. J. Lukiw, “Increased expression of miRNA-146a in Alzheimer's disease transgenic mouse models,” Neuroscience Letters, vol. 487, no. 1, pp. 94–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Zhang, L.-Y. Dong, Y.-J. Li, Z. Hong, and W.-S. Wei, “The microRNA miR-181c controls microglia-mediated neuronal apoptosis by suppressing tumor necrosis factor,” Journal of Neuroinflammation, vol. 9, article 211, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. Y.-N. Lv, A.-J. Ou-yang, and L.-S. Fu, “MicroRNA-27a negatively modulates the inflammatory response in lipopolysaccharide-stimulated microglia by targeting TLR4 and IRAK4,” Cellular and Molecular Neurobiology, pp. 1–16, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. K. G. Mawuenyega, W. Sigurdson, V. Ovod et al., “Decreased clearance of CNS β-amyloid in Alzheimer's disease,” Science, vol. 330, no. 6012, p. 1774, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. S. A. Grathwohl, R. E. Kälin, T. Bolmont et al., “Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia,” Nature Neuroscience, vol. 12, no. 11, pp. 1361–1363, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Shibuya, Z. Niu, E. Y. Bryleva et al., “Acyl-coenzyme A: CHolesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage,” Neurobiology of Aging, vol. 36, no. 7, pp. 2248–2259, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. W. J. Streit, H. Braak, Q.-S. Xue, and I. Bechmann, “Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease,” Acta Neuropathologica, vol. 118, no. 4, pp. 475–485, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. M.-V. Guillot-Sestier, K. R. Doty, D. Gate et al., “Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology,” Neuron, vol. 85, no. 3, pp. 534–548, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. S. W. Scheff, D. A. Price, F. A. Schmitt, M. A. Scheff, and E. J. Mufson, “Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 547–557, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. S. W. Scheff, D. A. Price, M. A. Ansari et al., “Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 43, no. 3, pp. 1073–1090, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. P. F. Chapman, G. L. White, M. W. Jones et al., “Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice,” Nature Neuroscience, vol. 2, no. 3, pp. 271–276, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. S. W. Scheff, D. L. Sparks, and D. A. Price, “Quantitative assessment of synaptic density in the outer molecular layer of the hippocampal dentate gyrus in Alzheimer's disease,” Dementia, vol. 7, no. 4, pp. 226–232, 1996. View at Google Scholar · View at Scopus
  59. E. Masliah, L. Crews, and L. Hansen, “Synaptic remodeling during aging and in Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 9, no. 3, pp. 91–99, 2006. View at Google Scholar · View at Scopus
  60. D. L. King and G. W. Arendash, “Maintained synaptophysin immunoreactivity in Tg2576 transgenic mice during aging: correlations with cognitive impairment,” Brain Research, vol. 926, no. 1-2, pp. 58–68, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Dong, M. V. Martin, S. Chambers, and J. G. Csernansky, “Spatial relationship between synapse loss and β-amyloid deposition in Tg2576 mice,” Journal of Comparative Neurology, vol. 500, no. 2, pp. 311–321, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Alonso-Nanclares, P. Merino-Serrais, S. Gonzalez, and J. DeFelipe, “Synaptic changes in the dentate gyrus of APP/PS1 transgenic mice revealed by electron microscopy,” Journal of Neuropathology and Experimental Neurology, vol. 72, no. 5, pp. 386–395, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. P. N. Lacor, M. C. Buniel, L. Chang et al., “Synaptic targeting by Alzheimer's-related amyloid β oligomers,” Journal of Neuroscience, vol. 24, no. 45, pp. 10191–10200, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. T. L. Spires, M. Meyer-Luehmann, E. A. Stern et al., “Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy,” Journal of Neuroscience, vol. 25, no. 31, pp. 7278–7287, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Yoshiyama, M. Higuchi, B. Zhang et al., “Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model,” Neuron, vol. 53, no. 3, pp. 337–351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. L. M. Ittner, Y. D. Ke, F. Delerue et al., “Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models,” Cell, vol. 142, no. 3, pp. 387–397, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. P. G. Ridge, M. T. W. Ebbert, and J. S. K. Kauwe, “Genetics of Alzheimer's disease,” BioMed Research International, vol. 2013, Article ID 254954, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. R. H. Swerdlow, J. M. Burns, and S. M. Khan, “The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1842, no. 8, pp. 1219–1231, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. S. M. Kilbride, J. E. Telford, K. F. Tipton, and G. P. Davey, “Partial inhibition of complex I activity increases Ca2+-independent glutamate release rates from depolarized synaptosomes,” Journal of Neurochemistry, vol. 106, no. 2, pp. 826–834, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. R. C. Paolicelli, G. Bolasco, F. Pagani et al., “Synaptic pruning by microglia is necessary for normal brain development,” Science, vol. 333, no. 6048, pp. 1456–1458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Ueno, Y. Fujita, T. Tanaka et al., “Layer V cortical neurons require microglial support for survival during postnatal development,” Nature Neuroscience, vol. 16, no. 5, pp. 543–551, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Squarzoni, G. Oller, G. Hoeffel et al., “Microglia modulate wiring of the embryonic forebrain,” Cell Reports, vol. 8, no. 5, pp. 1271–1279, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Audoy-Rémus, L. Bozoyan, A. Dumas et al., “GPR84 deficiency reduces microgliosis, but accelerates dendritic degeneration and cognitive decline in a mouse model of Alzheimer's disease,” Brain, Behavior, and Immunity, vol. 46, pp. 112–120, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. K. Bisht, K. P. Sharma, C. Lecours et al., “Dark microglia: a new phenotype predominantly associated with pathological states,” Glia, vol. 64, no. 5, pp. 826–839, 2016. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Seshadri, A. L. Fitzpatrick, M. A. Ikram et al., “Genome-wide analysis of genetic loci associated with Alzheimer disease,” The Journal of the American Medical Association, vol. 303, no. 18, pp. 1832–1840, 2010. View at Google Scholar
  76. J. C. Lambert, C. A. Ibrahim-Verbaas, D. Harold et al., “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease,” Nature Genetics, vol. 45, no. 12, pp. 1452–1458, 2013. View at Google Scholar
  77. B. A. Benitez, B. Cooper, P. Pastor et al., “TREM2 is associated with the risk of Alzheimer's disease in Spanish population,” Neurobiology of Aging, vol. 34, no. 6, pp. 1711.e15–1711.e17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Giraldo, F. Lopera, A. L. Siniard et al., “Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease,” Neurobiology of Aging, vol. 34, no. 8, pp. 2077.e11–2077.e18, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. J. D. Gonzalez Murcia, C. Schmutz, C. Munger et al., “Assessment of Trem2 Rs75932628 association with Alzheimer's disease in a population-based sample: the cache county study,” Neurobiology of Aging, vol. 34, no. 12, pp. e2811–2883, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Guerreiro, A. Wojtas, J. Bras et al., “TREM2 variants in Alzheimer's disease,” New England Journal of Medicine, vol. 368, no. 2, pp. 117–127, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Pottier, D. Wallon, S. Rousseau et al., “TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 35, no. 1, pp. 45–49, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Cuyvers, K. Bettens, S. Philtjens et al., “Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia,” Neurobiology of Aging, vol. 35, no. 3, pp. 726.e11–726.e19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. S. E. Hickman, N. D. Kingery, T. K. Ohsumi et al., “The microglial sensome revealed by direct RNA sequencing,” Nature Neuroscience, vol. 16, no. 12, pp. 1896–1905, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. O. Butovsky, M. P. Jedrychowski, C. S. Moore et al., “Identification of a unique TGF-β-dependent molecular and functional signature in microglia,” Nature Neuroscience, vol. 17, no. 1, pp. 131–143, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. D. J. Owen, P. Wigge, Y. Vallis, J. D. A. Moore, P. R. Evans, and H. T. McMahon, “Crystal structure of the amphiphysin-2 SH3 domain and its role in the prevention of dynamin ring formation,” The EMBO Journal, vol. 17, no. 18, pp. 5273–5285, 1998. View at Publisher · View at Google Scholar · View at Scopus
  86. I. Prokic, B. S. Cowling, and J. Laporte, “Amphiphysin 2 (BIN1) in physiology and diseases,” Journal of Molecular Medicine, vol. 92, no. 5, pp. 453–463, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Griciuc, A. Serrano-Pozo, A. R. Parrado et al., “Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta,” Neuron, vol. 78, no. 4, pp. 631–643, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Frank, G. J. Burbach, M. Bonin et al., “TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice,” Glia, vol. 56, no. 13, pp. 1438–1447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. L. Zhong, X.-F. Chen, Z.-L. Zhang et al., “DAP12 stabilizes the C-terminal fragment of the triggering receptor expressed on myeloid cells-2 (TREM2) and protects against LPS-induced pro-inflammatory response,” Journal of Biological Chemistry, vol. 290, no. 25, pp. 15866–15877, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. Y. Wang, M. Cella, K. Mallinson et al., “TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model,” Cell, vol. 160, no. 6, pp. 1061–1071, 2015. View at Publisher · View at Google Scholar · View at Scopus
  91. T. Jiang, Y.-D. Zhang, Q. Chen et al., “TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice,” Neuropharmacology, vol. 105, pp. 196–206, 2016. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Fuhrmann, T. Bittner, C. K. E. Jung et al., “Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease,” Nature Neuroscience, vol. 13, no. 4, pp. 411–413, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. D. P. Schafer, E. K. Lehrman, A. G. Kautzman et al., “Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner,” Neuron, vol. 74, no. 4, pp. 691–705, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. A. R. Bialas and B. Stevens, “TGF-β signaling regulates neuronal C1q expression and developmental synaptic refinement,” Nature Neuroscience, vol. 16, no. 12, pp. 1773–1782, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. C. M. William, M. L. Andermann, G. J. Goldey et al., “Synaptic plasticity defect following visual deprivation in Alzheimer's disease model transgenic mice,” Journal of Neuroscience, vol. 32, no. 23, pp. 8004–8011, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Syken, T. GrandPre, P. O. Kanold, and C. J. Shatz, “PirB restricts ocular-dominance plasticity in visual cortex,” Science, vol. 313, no. 5794, pp. 1795–1800, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. T. Kim, G. S. Vidal, M. Djurisic et al., “Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model,” Science, vol. 341, no. 6152, pp. 1399–1404, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. J. K. Atwal, J. Pinkston-Gosse, J. Syken et al., “PirB is a functional receptor for myelin inhibitors of axonal regeneration,” Science, vol. 322, no. 5903, pp. 967–970, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Datwani, M. J. McConnell, P. O. Kanold et al., “Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity,” Neuron, vol. 64, no. 4, pp. 463–470, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. M. T. Lin and M. F. Beal, “Alzheimer's APP mangles mitochondria,” Nature Medicine, vol. 12, no. 11, pp. 1241–1243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. P. H. Reddy, “Mitochondrial medicine for aging and neurodegenerative diseases,” NeuroMolecular Medicine, vol. 10, no. 4, pp. 291–315, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. H. Du, L. Guo, S. Yan, A. A. Sosunov, G. M. McKhann, and S. S. Yan, “Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 43, pp. 18670–18675, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. J. W. Lustbader, M. Cirilli, C. Lin et al., “ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease,” Science, vol. 304, no. 5669, pp. 448–452, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Oddo, A. Caccamo, J. D. Shepherd et al., “Triple-transgenic model of Alzheimer's Disease with plaques and tangles: intracellular Aβ and synaptic dysfunction,” Neuron, vol. 39, no. 3, pp. 409–421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. N. Alikhani, L. Guo, S. Yan et al., “Decreased proteolytic activity of the mitochondrial amyloid-β degrading enzyme, PreP peptidasome, in alzheimer's disease brain mitochondria,” Journal of Alzheimer's Disease, vol. 27, no. 1, pp. 75–87, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. J. Valla, L. Schneider, T. Niedzielko et al., “Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment,” Mitochondrion, vol. 6, no. 6, pp. 323–330, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. D. Fang, Z. Zhang, H. Li et al., “Increased electron paramagnetic resonance signal correlates with mitochondrial dysfunction and oxidative stress in an Alzheimer's disease mouse brain,” Journal of Alzheimer's Disease, vol. 51, no. 2, pp. 571–580, 2016. View at Publisher · View at Google Scholar · View at Scopus
  108. M. T. Heneka, M. J. Carson, J. E. Khoury et al., “Neuroinflammation in Alzheimer's disease,” The Lancet Neurology, vol. 14, no. 4, pp. 388–405, 2015. View at Publisher · View at Google Scholar
  109. K. I. Mosher and T. Wyss-Coray, “Microglial dysfunction in brain aging and Alzheimer's disease,” Biochemical Pharmacology, vol. 88, no. 4, pp. 594–604, 2014. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Heslegrave, W. Heywood, R. Paterson et al., “Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease,” Molecular Neurodegeneration, vol. 11, no. 1, article 3, 2016. View at Publisher · View at Google Scholar · View at Scopus
  111. L. Piccio, Y. Deming, J. L. Del-Águila et al., “Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status,” Acta Neuropathologica, vol. 131, no. 6, pp. 925–933, 2016. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Suárez-Calvet, G. Kleinberger, M. Á. Araque Caballero et al., “sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers,” EMBO Molecular Medicine, vol. 8, no. 5, pp. 466–476, 2016. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Matarin, D. A. Salih, M. Yasvoina et al., “A Genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology,” Cell Reports, vol. 10, no. 4, pp. 633–645, 2015. View at Publisher · View at Google Scholar · View at Scopus
  114. T. Kambe, Y. Motoi, R. Inoue et al., “Differential regional distribution of phosphorylated tau and synapse loss in the nucleus accumbens in tauopathy model mice,” Neurobiology of Disease, vol. 42, no. 3, pp. 404–414, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Lamkanfi, J. L. Mueller, A. C. Vitari et al., “Glyburide inhibits the Cryopyrin/Nalp3 inflammasome,” Journal of Cell Biology, vol. 187, no. 1, pp. 61–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. J.-Q. Shi, C.-C. Zhang, X.-L. Sun et al., “Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of nuclear factor-κB and NLRP3 inflammasome activation,” CNS Neuroscience and Therapeutics, vol. 19, no. 4, pp. 262–268, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Cassidy-Stone, J. E. Chipuk, E. Ingerman et al., “Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization,” Developmental Cell, vol. 14, no. 2, pp. 193–204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Cui, X. Tang, W. V. Christian, Y. Yoon, and K. Tieu, “Perturbations in mitochondrial dynamics induced by human mutant PINK1 can be rescued by the mitochondrial division inhibitor mdivi-1,” Journal of Biological Chemistry, vol. 285, no. 15, pp. 11740–11752, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. C. Zou, Y. Shi, J. Ohli, U. Schüller, M. M. Dorostkar, and J. Herms, “Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer’s disease,” Acta Neuropathologica, vol. 131, no. 2, pp. 235–246, 2016. View at Publisher · View at Google Scholar · View at Scopus
  120. E. E. Spangenberg, R. J. Lee, A. R. Najafi et al., “Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology,” Brain, vol. 139, no. 4, pp. 1265–1281, 2016. View at Publisher · View at Google Scholar · View at Scopus
  121. A. Olmos-Alonso, S. T. T. Schetters, S. Sri et al., “Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology,” Brain, vol. 139, no. 3, pp. 891–907, 2016. View at Publisher · View at Google Scholar · View at Scopus
  122. J. Bruttger, K. Karram, S. Wörtge et al., “Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system,” Immunity, vol. 43, no. 1, pp. 92–107, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Yamanaka, T. Ishikawa, A. Griep, D. Axt, M. P. Kummer, and M. T. Heneka, “PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice,” The Journal of Neuroscience, vol. 32, no. 48, pp. 17321–17331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  124. A. D. Bachstetter, C. M. Norris, P. Sompol et al., “Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of alzheimer's disease-related pathology,” Journal of Neuroscience, vol. 32, no. 30, pp. 10201–10210, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. H. Zhang, Y. Li, J. Yu et al., “Rho kinase inhibitor fasudil regulates microglia polarization and function,” NeuroImmunoModulation, vol. 20, no. 6, pp. 313–322, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. K. Kobayashi, S. Imagama, T. Ohgomori et al., “Minocycline selectively inhibits M1 polarization of microglia,” Cell Death and Disease, vol. 4, no. 3, article e525, 2013. View at Publisher · View at Google Scholar · View at Scopus
  127. D. A. Rossignol and R. E. Frye, “Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism,” Frontiers in Physiology, vol. 5, article 150, 2014. View at Publisher · View at Google Scholar · View at Scopus